Zhou Xianjing, Lai Zhencheng, Li Jiaming, Fan Chengcheng, Cui Sunliang
Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Department of Burns and Wound Care, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Acc Chem Res. 2025 Jul 1. doi: 10.1021/acs.accounts.5c00338.
ConspectusThe development of efficient multicomponent reactions (MCRs) represents a vital frontier for the rapid construction of structurally sophisticated molecules from simple precursors in an atom- and step-economic manner. In particular, the Mannich reaction is a prototypical three-component reaction that rapidly assembles a resonance-stabilized carbon nucleophile, an aldehyde (or ketone), and an amine to afford alkylamines and serves as a particularly valuable tool for diversity-oriented synthesis in drug discovery and development. Typically, the nucleophilic components of the Mannich reaction rely on Brønsted-acidic carbonyl C()-H and electron-rich aromatic C()-H. However, the development of Mannich reactions involving unactivated C()-H remains a formidable challenge, which would be largely attributed to their difficult deprotonation and therefore non-nucleophilic properties.In this Account, we detail the journey from a serendipitous discovery to mechanistic elucidation, wherein an unprecedented double Mannich alkylamination occurred in both C()-H and unactivated benzylic C()-H bonds to eventually enable alkylaminative cyclization. Mechanistic studies revealed a distinctive pathway in which a multiple Mannich and -Mannich process and the dehydrogenation of benzylic C()-H bonds were key steps to constitute the alkylamination. Enlightened by the mechanistic investigations, our group successfully developed a series of Mannich-type MCRs in which benzofurans/indoles, formaldehyde, and alkylamine hydrochlorides assemble efficiently to furnish piperidine-fused benzofurans/indoles, demonstrating broad compatibility with medicinally relevant functionalities. Inspired by the dual C()-H/C()-H alkylaminative cyclization paradigm, we developed a unique Mannich-type MCR of indoles wherein the MCR process occurred in both N-H and the adjacent 2-position C()-H bonds to access indole-fused seven-membered heterocycles.More importantly, these MCRs serve as a powerful synthetic toolbox in the scaffold evolution of natural products as well as in drug discovery and development. Notably, the modification of natural products (NPs) presents significant challenges due to their inherent structural complexity, and thus efficient synthetic methods could enable more accessible modification of NPs, thereby unlocking their full therapeutic potential. We employed our established MCRs to successfully achieve an innovative scaffold evolution of natural product tanshinones, in which the highly lipophilic tanshinones could be easily transformed to -heterocyclic scaffolds with improved functionality, drug-likeness, and biological specificity. As a result, we have pioneered the chemical evolution of Tan I for the discovery of a new class of potent NLRP3 inflammasome inhibitors and the chemical evolution of Tan IIA for the effective treatment of ALI. Furthermore, leveraging these MCRs to access a privileged scaffold, we have successfully developed a number of promising candidates, including the novel HDAC inhibitors, intestine specific P-gp inhibitors, and STAT3 inhibitors, each showing significant potential for further advancement. Finally, it is anticipated that these MCRs will become essential tools in modern medicinal chemistry and expedite the discovery of new therapeutic agents.
综述
高效多组分反应(MCRs)的发展是利用原子经济性和步骤经济性,从简单前体快速构建结构复杂分子的关键前沿领域。特别是,曼尼希反应是一种典型的三组分反应,它能迅速将共振稳定的碳亲核试剂、醛(或酮)和胺组装在一起,生成烷基胺,是药物发现和开发中用于多样性导向合成的特别有价值的工具。通常,曼尼希反应的亲核组分依赖于布朗斯特酸性的羰基C()-H和富电子的芳香族C()-H。然而,涉及未活化C()-H的曼尼希反应的发展仍然是一项艰巨的挑战,这在很大程度上归因于其难以脱质子化,因此具有非亲核性质。
在本综述中,我们详细介绍了从偶然发现到机理阐明的过程,其中在C()-H和未活化的苄基C()-H键中都发生了前所未有的双曼尼希烷基化反应,最终实现了烷基胺化环化。机理研究揭示了一条独特的途径,其中多个曼尼希和 -曼尼希过程以及苄基C()-H键的脱氢是构成烷基化的关键步骤。受机理研究的启发,我们小组成功开发了一系列曼尼希型MCRs,其中苯并呋喃/吲哚、甲醛和烷基胺盐酸盐有效地组装在一起,生成哌啶稠合的苯并呋喃/吲哚,证明了与药物相关官能团具有广泛的兼容性。受双C()-H/C()-H烷基胺化环化模式的启发,我们开发了一种独特的吲哚曼尼希型MCR,其中MCR过程在N-H和相邻的2-位C()-H键中都发生,以获得吲哚稠合的七元杂环。
更重要的是,这些MCRs在天然产物的骨架演化以及药物发现和开发中是强大的合成工具箱。值得注意的是,天然产物(NPs)的修饰由于其固有的结构复杂性而面临重大挑战,因此高效的合成方法可以使NPs的修饰更容易实现,从而释放其全部治疗潜力。我们利用已建立的MCRs成功实现了天然产物丹参酮的创新骨架演化,其中高度亲脂性的丹参酮可以很容易地转化为具有改善的功能、类药性和生物学特异性的 -杂环骨架。结果,我们率先对丹参酮I进行化学演化以发现一类新的强效NLRP3炎性小体抑制剂,并对丹参酮IIA进行化学演化以有效治疗急性肺损伤。此外,利用这些MCRs获得一个优势骨架,我们成功开发了许多有前景的候选药物,包括新型HDAC抑制剂、肠道特异性P-糖蛋白抑制剂和STAT3抑制剂,每一种都显示出进一步发展的巨大潜力。最后,预计这些MCRs将成为现代药物化学中的重要工具,并加速新治疗剂的发现。